NCT00571662 · OUTCOME

Percent of Participants With Chimerism: Full Donor Chimerism Defined as >95% Donor CD3+ Cell in Blood as Assessed by DNA Fingerprinting

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant · Source last updated 2023-10-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

the efficacy of the regimen as determined by engraftment rate and establishment of donor hematopoietic chimerism at day +28 and day +70.

Pentostatin to be administered intravenously on days -10, -9, and -8 at a dose of 4mg/m2/day

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Cohort I	68

Day 28

Values in percent of participants · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Cohort I	85	Not reported	40	100	Not reported

Day 70

Values in percent of participants · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Cohort I	90	Not reported	45	100	Not reported

Complete source fields

classes

denoms

description

the efficacy of the regimen as determined by engraftment rate and establishment of donor hematopoietic chimerism at day +28 and day +70.

dispersion Type

Full Range

groups

param Type

MEDIAN

reporting Status

POSTED

time Frame

days +28 and +70

title

Percent of Participants With Chimerism: Full Donor Chimerism Defined as >95% Donor CD3+ Cell in Blood as Assessed by DNA Fingerprinting

type

PRIMARY

unit Of Measure

percent of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice